The Trouble With KRAS - Cancer Commons
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) - ScienceDirect
KRAS testing is a screening of non-responders to anti-EGFR therapy.... | Download Scientific Diagram
IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar
Systemic treatment for metastatic colorectal cancer
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study - The Lancet Oncology
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020 | Published in healthbook TIMES Oncology Hematology
The current understanding on the impact of KRAS on colorectal cancer - ScienceDirect
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study - Chida - 2021 - The Oncologist - Wiley Online Library
Frontiers | Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors
Cells | Free Full-Text | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy | Annals of Surgical Oncology
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer | Semantic Scholar
Targeting the untargetable KRAS in cancer therapy - ScienceDirect
EGFR and bevacizumab in first-line KRAS wild-type tumours: randomized... | Download Scientific Diagram
KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI
